Table 1 Results of irradiation using SBRT
From: Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review
Study | Study design | No. of patients | Previous radiotherapy | Follow-up, mo | Tumor volume, median (range), cm3 | No. of fractions, median (range) | Total dose, median (range), Gy | Efficacy | Severe toxicity | References |
|---|---|---|---|---|---|---|---|---|---|---|
Jean-Claude Rwigema, 2010 | R | 85 | Median time to previous irradiation: 19.4 mo (range, 1.0–601.8 mo); Median prior BED10: 70 Gy (range, 32–170.7 Gy) | 6 (1.3–39) | Tumor volume: 25.1 (2.5–162) | 5 (1–5) | 35 (15–44) | 1-year LC: 51.2%; 2-year LC: 30.7%; 1-year OS: 48.5%; 2-year OS: 16.1%; Median OS: 11.5 mo | Grade 3 acute toxicities: 4.7% | [8] |
Jean-Claude Rwigema, 2011 | R | 96 | Median interval to failure from prior irradiation: 16 mo (range, 4.6–423.1 mo); Median dose of prior irradiation: 68.4 Gy (range, 32–170.7 Gy) | 14 (2–39) | GTV: 24.3 (2.5–162) | 5 (1–5) | 35 (15–50) | 1-year OS: 58.9%; 2-year OS: 28.4%; Doses 40 to 50 Gy: 1-year LRC: 69.4%; 2-year LRC: 57.8%; 3-year LRC: 41.1%; Doses 15 to 36 Gy: 1-year LRC: 51.9%; 2-year LRC: 31.7%; 3-year LRC: 15.9% | Grade 3 acute toxicities: 5.2%; Grade 3 late toxicities: 3.1% | [3] |
Mustafa Cengiz, 2011 | R | 46 | Median time to previous irradiation: 38 mo (range, 3.8–306 mo); Median dose of prior irradiation: 61 Gy (range, 30–70 Gy) | 7 (2–23) | Tumor volume: 45 (3–206) | 5 (1–5) | 30 (18–35) | 1-year PFS: 41%; Median PFS: 10.5 mo; 1-year OS: 46%; Median OS: 11.93 mo | Grade 3 acute dermatitis and mucositis: 4.4%; Grade ≥ 2 late toxicities: 13.3% | [9] |
Bénédicte Comet, 2012 | P | 40 | Median time to previous irradiation: 31.6 mo (range, 7.9–263.7 mo); Median dose of prior irradiation: 66 Gy (range, 18–192 Gy) | 25.6 | PTV: 64.1 (4.7–295.6) | 6 | 36 | Median relapse-free survival: 8.8 mo; Response rate: 79.4%; 1-year OS: 58%; 2-year OS: 24%; Median OS: 13.6 mo | Grade 3 toxicities: 10.3% | [17] |
Pierluigi Bonomo, 2014 | R | 17 | Median time to previous irradiation: 24 mo (range, 10–168 mo); Median dose of prior irradiation: 66 Gy (range, 50–70 Gy) | 7.5 (2–17) | GTV: 58.7 (8.5–211.3) | 5 | 30 (25–35) | CR: 25%; PR: 31%; SD: 44% | Grade 3 mucositis: 6% | [20] |
Hideya Yamazaki, 2016 | R | 107 | Median time to previous irradiation: 14.5 mo (range, 0.7–1180 mo); Median dose of prior irradiation: 60 Gy (range, 40–116 Gy) | 15 (10–122) | PTV: 28.4 (1–339) | 5 (3–8) | 30 (15–39) | 2-year LRC: 64%; 1-year OS: 55%; 2-year OS: 35%; Median OS: 14.4 mo | Grade ≥ 3 toxicities: 21% | [21] |
John A Vargo, 2018 | Retrospective comparative analysis | 197 | Median time to previous irradiation: 14.4 mo (range, 1.2–420 mo); Median dose of prior irradiation: 70 Gy (range, 40–170.7 Gy) | 7.1 (1–120) | GTV: 30 (1–427) | 5 (1–8) | 40 (16–50) | Cumulative LRF: 57.0%; 2-year OS: 16.3%; Median OS: 7.8 mo | Grade ≥ 3 acute toxicities: 11.7%; Grade ≥ 3 late toxicities: 11.6% | [22] |
Luke Stanisce, 2018 | R | 25 | Median time to previous irradiation: 14 mo (range, 3–72 mo); Median dose of prior irradiation: 70 Gy (range, 30–110 Gy) | NA | GTV: 31.75 (5.5–121.8) | 5 (3–5) | 40 (24–44) | LF: 32%; Median LF: 5.8 mo; LRF: 28%; Median LRF: 8.5 mo; 1-year OS: 32%; 2-year OS: 16%; Median OS: 7.5 mo | Grade 3 acute toxicities: 4%; Grade 3 late toxicities: 6% | [23] |